Viamet Pharmaceuticals Announces Agreement with NIAID to Advance Novel Class of Broad-Spectrum Antifungal Compounds
June 19, 2012, Research Triangle Park, North Carolina – Viamet Pharmaceuticals, Inc., a world leader in the development of “best-in-class” products targeting metalloenzymes, announced today that it has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Under this agreement, Viamet will utilize NIAID’s preclinical services program to further develop a novel class of broad-spectrum antifungal agents conceived by Viamet.
“Viamet is very pleased to receive the support of NIAID to advance a new generation of novel antifungal agents,” said Robert Schotzinger, M.D., Ph.D., President and Chief Executive Officer of Viamet. “This new class of compounds holds great promise for the treatment of a broad range of life-threatening infections in patients caused by yeasts and molds. As with bacterial infections, the number and severity of infections caused by pathogenic fungi continue to increase at an alarming pace. Viamet is one of the few companies focused on solutions to this increasing threat to human health.”
Using its proprietary Metallophile® Technology, Viamet has been able to build a broad portfolio of novel agents that target a range of fungal pathogens. VT-1161 is a potent, oral agent completing Phase 1 clinical testing for the treatment of a diverse set of fungal infections, including onychomycosis. VT-1129 is a potent, oral agent undergoing preclinical development through a collaboration with the Therapeutics for Rare and Neglected Diseases program, which is administered by the NIH’s National Center for Advancing Translational Sciences.
Under the terms of the agreement, NIAID?funded contractors will conduct chemical synthesis of novel antifungal compounds conceived by Viamet using its Metallophile® Technology. Viamet will retain exclusive rights to the compounds and will undertake additional testing of the synthesized molecules.
About Viamet Pharmaceuticals, Inc. (www.viamet.com)
Viamet Pharmaceuticals, Inc. discovers and develops “best-in-class” inhibitors of metalloenzymes via an innovative and proprietary platform, called the Metallophile® Technology. The Metallophile® Technology is based on our world-class expertise in bioinorganic chemistry and an extensive understanding of metalloenzyme structure and function. Using the Metallophile® Technology, we can rapidly and cost-effectively generate best-in-class, patentable, small molecule inhibitors of metalloenzymes by optimizing the metal-binding component of existing compounds.
Viamet Pharmaceuticals, Inc. is a wholly-owned subsidiary of Viamet Pharmaceuticals Holdings, LLC. VPS-1, Inc., an operating subsidiary of Viamet Pharmaceuticals Holdings, LLC, is developing VT-1161 under license from Viamet Pharmaceuticals, Inc.